Abstract. Monocyte chemoattractant protein-1 (MCP-1) has been demonstrated to play a role in tumor progression. The present study examined the MCP-1 expression of colorectal liver metastases and determined whether MCP-1 is related to tumor progression and is a predictive marker for survival after hepatic resection of colorectal liver metastases. Eightyseven patients with colorectal liver metastases were evaluated by immunohistochemistry of MCP-1, Angiopoietin-2, CD68, and CD34 for determination of microvessel density. Clinicopatholgical data were also examined. In a separate experiment, immunohistochemistry of MCP-1 was performed to investigate the expression of primary colorectal tumor according to the clinical stage. MCP-1 mRNA expression was determined in colorectal cancer cell lines. Forty-nine patients (56%) showed high expression of MCP-1 of colorectal liver metastases. High MCP-1 expression was related to multiple colorectal liver metastases. When the degree of MCP-1 expression increased, microvessel density count significantly increased compared with low MCP-1 expression. The MCP-1 expression correlated with Angiopoietin-2 expression. MCP-1 expression of the primary colorectal cancer increased as the clinical stage advanced. The increased MCP-1 mRNA expression was observed in cancer cell lines which have high metastasis potency. Univariate analysis demonstrated that the timing of metastases, tumor size, number of metastases, and MCP-1 expression were significant prognostic factors. Multivariate analysis demonstrated that MCP-1 expression was a significant prognostic factor in hepatic disease-free survival. The MCP-1 expression in colorectal liver metastases, at least in part, may be associated with angiogenesis and be a predictive marker for hepatic recurrence after hepatic resection for colorectal liver metastases.
Introduction
Colorectal carcinoma is among the most frequent malignant diseases worldwide, and is one of the leading causes of cancer related deaths. A significant number of patients with colorectal carcinoma who undergo curative resection unfortunately develop distant metastasis leading to a poor survival (1) . The most common distant metastasis of colorectal carcinoma is to the liver, which is often associated with a poor prognosis (2, 3) . Hepatic resection is a potentially curative therapy for colorectal liver metastases. However, recurrence (both intrahepatic and extrahepatic) occurs in approximately 60-70% of the patients after hepatectomy, suggesting that patients with colorectal liver metastasis would not always benefit from hepatectomy. Previous reports have mentioned that the timing of liver metastasis, the number of liver metastases, the presence of lymph node metastasis of the primary tumor, the presence of hilar lymph node metastasis, and the absence of fibrous capsule of the metastatic tumor are prognostic factors for survival (4) (5) (6) (7) (8) (9) . However, the prognostic factors for survival which are obtained from the resected specimens and the mechanism of tumor progression of the metastases have not been well elucidated.
Interaction between tumor and stromal cells may influence the tumor progression. Tumor associated macrophages which are major components of stroma have been reported to have certain roles in tumor progression (10) . Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a member of the C-C chemokines that accumulate and influence macrophages/monocytes and lymphocytes which are involved in tumor progression and metastasis (11) . The expression of MCP-1 has been reported in several tumor types including human melanoma, ovarian cancer, and esophageal cancer (12) (13) (14) . However, only a few studies demonstrating MCP-1 expression and its biological role in colorectal carcinoma are available to date, and there are no studies investigating the correlation between survival and MCP-1 expression of colorectal liver metastasis (15) (16) (17) . Although colorectal liver metastasis is considered to be a hypovascular lesion, it appears that the periphery of the metastatic lesion retains rich vascularity (18 (19) implies that angiogenesis may play a role in tumor progression in patients with colorectal liver metastasis. MCP-1 is a potent angiogenic factor in several carcinomas (20, 21) . MCP-1 expression in breast cancer tissue has been reported to closely correlate with the concentrations of thymidine phosphorylase and VEGF, which are major components of angiogenic factors (22) . We hypothesized that MCP-1 may play a role in tumor progression of colorectal liver metastases. The objective of this study was to examine the expression of MCP-1 in colorectal liver metastasis and to determine whether MCP-1 influences tumor progression of colorectal liver metastasis by angiogenesis which is associated with survival.
Patients and methods
Patients and tissue samples. A total of 87 Japanese patients with colorectal liver metastases were selected from those who underwent curative hepatic resection (R0) at the Department of General Surgery at Chiba University (Chiba, Japan) between 1999 and 2006. Written informed consent was obtained from all the patients in accord with the ethical standards of the Helsinki Declaration of 1975. The medical records of these patients were retrospectively reviewed. In this study, synchronous metastases were defined as metastases diagnosed before colorectal surgery or at the time of surgery. The patients were followed for survival until death or June 30, 2008 . The median follow-up time was 30 months (range 8-115 months). The clinicopathological characteristics of these patients are shown in Table I . In a separate experiment, two patients having high grade adenoma and three in each group having colorectal cancer of stage 0 (TNM classification), stage III, and stage IV were selected. H&E staining and immunohistochemistry. Tissue sections (4-μm thick) were prepared from formalin-fixed paraffinembedded blocks and stained with H&E solution. Immunohistochemistry was done using either CSA II kit or EnVision + kit (Dako Cytomation, Carpinteria, CA) according to the manufacturer's instructions. The microwave antigen retrieval technique was used in all the cases. The series and dilutions used in the present study were as follows: a) anti-human MCP-1/CCL2 mouse monoclonal antibody (R&D Systems), 1:50; b) anti-human CD34 mouse monoclonal antibody (Code NP036, Dako Cytomation), ready-to-use; c) anti-CD68 mouse monoclonal antibody (KP-1, Dako Cytomation), 1:100; d) anti-Angiopoietin-2 rabbit polyclonal antibody (sc-20718, Santa Cruz Biotechnology, Santa Cruz, CA), 1:50. Appropriate positive controls known to contain the antigens in question were processed simultaneously. Negative controls were performed without the primary antibody. The tissue sections were washed in water, counterstained with Mayer's hematoxylin. The immunohistochemical analyses were done in duplicate.
Evaluation of MCP-1 and angiopoietin-2.
Immunoreactivity was evaluated in a semiquantitative way assessing both staining intensity and percentage of positive cells. The expression of MCP-1 and Angiopoietin-2 was determined as follows: 0, no staining; 1, occasional weak staining; 2, moderate staining; 3, intense staining. To qualify for scores 2 and 3 (i.e., high expression), positive staining of >10% of tumor cells was required. The MCP-1 and Angiopoietin-2 expression was divided into two groups, the low expression group (scores 0 and 1) and the high expression group (scores 2 and 3). For the evaluation, a high-power field (x200) of 10 random areas (within the tumor) was selected. The evaluation of the immunohistochemistry was done by two investigators, T. Shida and Y. Nakatani who were not aware of the clinicopathological features and prognosis of the patients. When there was a split decision, reevaluation was done for consensus. The expressions of these molecules were evaluated both in the tumor site as well as in the invasion front of the tumor.
Evaluation of microvessel density (MVD).
MVD was assessed by immunohistochemistry of CD34. The tissue sections were scanned by light microscopy at a low power field (x40) and the vessel count in areas with the highest number of capillaries was assessed at a high power field (x200). The average counts of 5 fields were determined.
Evaluation of macrophages.
Macrophage was assessed by immunohistochemistry of CD68. The tissue sections were Table I . MCP-1 expression and patient characteristics. 
a P-value was determined by the ¯2 test. b P-value was determined by the Fisher's exact test.
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scanned by light microscopy at a low power field (x40) and areas with a high density of CD68 positive cells were selected. CD68 positive cells were counted at a high power field (x200) and the average counts of 5 fields were determined. According to the average number of CD68 positive cells per field (x200), the staining scores of CD68 were determined as follows: 0, 0-50 CD68 positive cells; 1, 51-100 CD68 positive cells; 2, 101-200 CD68 positive cells; 3, ≥201 CD68 positive cells.
Analysis of mRNA by reverse-transcription polymerase chain reaction (RT-PCR).
Extraction of total RNA from the cell lines was performed using RNeasy Mini kit (Qiagen, Tokyo, Japan) according to the manufacturer's instructions. Colorectal cancer cell lines were HT29, WiDr, SW48, and COLO201 (American Type Culture Collection, Manassas, VA). HT29 and WiDr are reported to have high metastatic potency (23) . SW48 and COLO201 are reported to have low metastatic potency (23) . Expression of MCP-1 was examined by reverse transcriptase-mediated polymerase chain reaction (RT-PCR) with the following primers: MCP-1 forward (CTC ATA GCA GCC ACC TTC AT), MCP-1 reverse (GCT TTT CCT CTT GAA CCA CA) to give a 495-bp product. GAPDH forward (TAC ACT GAG CAC CAG GTG GTC), GAPDH reverse (CCT GTT GCT GTA GCC AAA TTC G). For internal control, GAPDH cDNA was amplified. RT-PCR amplification was performed using AmpliTaq Gold PCR Master Mix (PE Applied Biosystems, Foster City, CA) and PCR thermocycler. After 10 min of initial melting at 95˚C, the mixture was amplified for a total of 35 cycles, using a 3-step cycle process that began with melting at 95˚C for 60 sec, annealing at 55˚C for 60 sec, followed by extension at 72˚C for 90 sec. The final cycle was followed by 12 min of soaking at 72˚C. Seven microliters of each RT-PCR reaction was electrophoresed in a 2.0% agarose gel and stained with ethidium bromide. RT-PCR was performed in a duplicate.
Statistical analysis. Data were compared using the MannWhitney U test or the Rank sum test. The associations between discrete variables were assessed using the ¯2 or Fisher's exact test. The Kaplan-Meier method was used to estimate recurrence or death, and the log-rank test was used to examine statistical significance. Multivariate analysis was determined by Cox proportional hazards model. The data were analyzed by using the SigmaStat 3.0 and SPSS 11.5 software program. All data were expressed as the mean ± SD. The results were considered significant when p<0.05 was obtained.
Results

MCP-1 expression of the metastatic liver tumor by immunohistochemistry.
To determine whether the MCP-1 expression of the metastatic liver tumor was increased in patients with colorectal liver metastases, immunohistochemistry of MCP-1 was performed (Fig. 1) . Of the 87 patients examined, 49 patients (56.3%) showed high expression of MCP-1 (equivalent to scores 2-3). The remaining 38 patients (43.7%) showed low expression of MCP-1 (equivalent to scores 0-1). The staining was observed in the cytoplasm of the tumor cells. Table I . The number of patients with multiple metastatic liver tumors significantly increased in the high MCP-1 expression group relative to that in the low MCP-1 expression group (p=0.029), while no significant difference was found in other clinicopathological parameters between the two groups.
Relationship of MCP-1 and CD68 expression.
One of the roles of MCP-1 has been reported to accumulate monocytes/ macrophages and lymphocytes including tumor-associated macrophages (11) . To determine whether the MCP-1 expression of the metastatic liver tumor was correlated with the accumulation of macrophages, we examined the expression of CD68 which is the marker of macrophages (24) and determined the staining scores as defined in the methods section. The results of the immunohistochemical staining scores are listed in Table II . While the accumulation of macrophages defined by CD68 immunohistochemistry in the tumor was observed, there was no correlation between the expression of MCP-1 and CD68 (Table II) .
Relationship of MCP-1, Angiopoietin-2, and MVD (CD34) expression.
MCP-1 has been demonstrated to be related with angiogenesis (22) . To determine whether the MCP-1 expression of the metastatic liver tumor correlated with angiogenesis, we examined the expression of CD34 and the MVD count. As the MCP-1 expression increased (scoring 2 and 3), the MVD count significantly increased in comparison to little MCP-1 expression (scoring 0, Fig. 2A ). An intense staining of Angiopoietin-2 expression of the tumor was correlated with an increase in the MVD count (Fig. 2B) . As shown in Table II , the expression of MCP-1 of the tumor positively correlated with Angiopoietin-2 expression (p=0.020).
MCP-1 expression of the primary colorectal cancer and clinical stage.
In a separate experiment, to determine whether the degree of MCP-1 expression was related to the clinical stage, we examined the MCP-1 expression by immunohistochemistry for the primary colorectal tumor stratified by the adenoma high grade or primary colorectal cancer defined by UICC classification. Little MCP-1 expression was observed in adenoma high grade (n=2) and stage 0 colorectal cancer (n=3, Fig. 3A and B) . As the clinical stage increased (III and IV), moderate MCP-1 expression was found in stage III colorectal cancer (n=3) and significantly intense MCP-1 expression was found in stage IV colorectal cancer (n=3) in comparison to the early stage colorectal cancer (Fig. 3C and D) .
MCP-1 mRNA expression of colon cancer cell lines.
To determine the MCP-1 expression of colon cancer cell lines, which are stratified by metastasis potency, RT-PCR was performed. MCP-1 mRNA expression was increased in cancer cell lines which have high metastasis potency such as HT29. On the contrary, MCP-1 mRNA expression was relatively decreased in cancer cell line with low metastasis potency such as SW48 and COLO201 (Fig. 4) .
MCP-1 expression and survival.
To determine whether the MCP-1 expression of the metastatic liver tumor was related to hepatic recurrence or overall survival after hepatic resection, we examined hepatic disease-free or overall survival with the Kaplan-Meier method. Most of hepatic recurrence was observed within 2 years after hepatectomy. The hepatic Table II . The correlation of MCP-1 expression with the expression of CD68 and Angiopoietin-2. --------------------------------------------- ----------------------------------------------- 
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disease-free survival was significantly lower in patients in the high MCP-1 expression group relative to patients in the low MCP-1 expression group (p=0.0014, Fig. 5A ). Although the follow-up periods may not be long enough, the overall survival in patients with high MCP-1 expression group was worse compared with low MCP-1 expression group (p=0.0407, Fig. 5B ).
To determine whether the MCP-1 expression was a significant prognostic factor for hepatic disease-free survival after hepatic resection, we performed both uni-and multivariate analyses. The univariate analysis demonstrated that the timing of hepatic metastases, tumor size, number of metastases, and MCP-1 expression of the tumor were significant prognostic factors (Table III) . The multivariate analysis showed that MCP-1 expression and the timing of hepatic metastases were significant independent prognostic factors for hepatic disease-free survival in patients with colorectal liver metastases (Table III) .
Discussion
This study revealed that MCP-1 is aberrantly expressed in subsets of metastatic colorectal liver tumors, and is related with a poor prognosis, especially with regard to intrahepatic recurrence. The expression of MCP-1 has been reported in several malignancies in relation to tumor progression, but only limited data are currently available with regard to colorectal carcinoma (12) (13) (14) (15) (16) (17) . Furthermore, no study has been performed on a large number of colorectal metastatic liver tumors with regard to the correlation between MCP-1 expression and prognosis.
The role for MCP-1 in tumor progression remains controversial (20, 25, 26 ). In the current study, the MCP-1 expression of primary colorectal cancer increased as the clinical stage (UICC classification) advanced, suggesting that MCP-1 appears to be related to metastasis potency of colorectal cancer. Along with this finding, MCP-1 mRNA expression was relatively increased in cancer cell lines which have high metastasis potency in comparison to those with low metastasis potency. Thus, these findings suggested that MCP-1 may play a certain role in tumor progression and metastasis.
One of the roles of MCP-1 is to recruit macrophages (11) . However, in the present study, no positive relationship was observed between the degree of MCP-1 expression and accumulation of tumor-associated macrophages. Although the expression of tumor-associated macrophages is reported to be associated with a poor prognosis in several malignancies (i.e., breast cancer, bladder cancer, and prostate cancer), as for colorectal carcinoma, the expression of tumorassociated macrophages has been reported with a favorable prognosis (24, 27, 28) . Therefore, the observation concerning tumor-associated macrophages and the prognosis in various cancers seems to be still a matter of debate. The accumulation of tumor-associated macrophages may promote tumor progression by altering the balance of the macrophages, however it may be a reflection of the increased inflammatory activity within cancer patients. The present data suggest that there may be other chemoattractants that would influence the accumulation of tumor-associated macrophages in colorectal liver metastasis. The relationship of MCP-1 expression and tumor-associated macrophages in colorectal liver metastases thus needs further investigation.
Another role for MCP-1 is a potent angiogenic factor (20, 21, 29) . The concentration of MCP-1 in breast cancer tissue has been reported to closely correlate with the concentrations of thymidine phosphorylase and VEGF, which are major components of angiogenic factors (22) . In the current study, a significant correlation was observed between the MCP-1 expression and microvessel density defined by CD34 immunohistochemistry in colorectal liver metastatic tumor. Consistent with this finding, MCP-1 has been demonstrated to be associated with tumor vessel density in human esophageal cancer (20) . Moreover, the MCP-1 expression was positively related with the Angiopoietin-2 expression which is a representative angiogenic factor. Angiopoietin-2 is one of the potent and crucial factors for angiogenesis, and its role has been previously studied in human hepatocellular carcinoma (30) . Concerning colorectal carcinoma, it has been revealed that Angiopoietin-2 contributes to angiogenesis and tumor growth leading to a shorter survival (31, 32) . These findings may support the present study that MCP-1, at least in part, may contribute to angiogenesis and be related to a poor survival in patients with colorectal liver metastasis. Thus, it Table III . Univariate and multivariate analysis of predictive factors for hepatic recurrence. 13% (14) Number of metastases ≤4 (n=71) 53% 0.0145 >5 (n=16)
25% (15) MCP-1 expression Low (n=38) 67% 0.0014 Figure 5 . (A), The hepatic disease-free survival rate stratified by high MCP-1 expression group (n=49) or low MCP-1 expression group (n=38). Hepatic disease-free survival of patients after hepatectomy was calculated by the Kaplan-Meier method. A comparison was performed using the log-rank test. High MCP-1 expression was significantly associated with shorter diseasefree survival (p=0.0140). (B) The overall survival rate stratified by high MCP-1 expression group (n=49) or low MCP-1 expression group (n=38). The overall survival of patients after hepatectomy was calculated by the Kaplan-Meier method. The comparison was performed using the log-rank test.
seems likely that the MCP-1 expression plays a role in angiogenesis in patients with colorectal liver metastasis.
Regarding the clinicopathological features, the high MCP-1 expression was associated with multiple colorectal metastatic liver tumors, suggesting that intrahepatic spread might be increased in patients with high MCP-1 expression of the tumors. Moreover, MCP-1 was a significant independent prognostic factor for the hepatic disease-free survival in comparison to other previously reported clinical factors (4) (5) (6) (7) (8) (9) . Thus, the MCP-1 expression of the metastatic liver tumor may be an indicator for the prediction of remnant liver recurrence. In overall survival, the MCP-1 expression also reached statistical difference, although the significance was less than that of hepatic disease-free survival. This may be explained by the fact that extrahepatic or other peritoneal recurrence was occurred in some patients with colorectal liver metastases after hepatectomy. Taken together, in patients with colorectal liver metastasis, it seems likely that MCP-1 plays crucial roles in not only angiogenic promotion but in biologically related aggressive behavior as well, and the score of MCP-1 expression of the metastatic liver tumors may be useful in predicting the clinical outcome of patients with colorectal liver metastases after hepatectomy.
In conclusion, the high expression of MCP-1 in tumors of colorectal metastases may cause tumor progression by angiogenesis and be useful in predicting hepatic recurrence and survival after hepatectomy. Further and a larger number of studies are needed to evaluate the more precise mechanism of MCP-1 in patients with colorectal liver metastasis.
